| Phase III Trial | Author | Year | N | Treatment Arms | ORR (%) | mPFS (m) | mOS (m) |
| Royal Mardsen (18) | Webb A | 1997 | 256 | ECF FAMTX | 45 21 | 7.4 3.4 | 8.9 5.7 |
| EORTC (19) | Vanhoefer U | 2000 | 399 | ELF FP4w FAMTX | 9 20 12 | 3.3 4.1 3.3 | 7.2 7.2 6.7 |
| V325 (20) | Ajani JA | 2007 | 445 | DCF FP4w | 37 25 | 5.6 3.7 | 9.2 8.6 |
| Chinese trial (23) | Wang J | 2015 | 243 | mDCF FP3w | 48.7 33.9 | 7.2 4.9 | 10.2 8.5 |
| ML 17032 (24) | Kang YK | 2009 | 316 | XP FP3w | 46 32 | 5.6 5.0 | 10.5 9.3 |
| REAL-2 (25) | Cunningham E | 2008 | 1002 | ECF ECX EOF EOX | 40.7 46.4 42.4 47.9 | 6.2 6.7 6.5 7.0 | 9.9 9.9 9.3 11.2 |
| AIO (26) | Al Batran SE | 2008 | 220 | FLO FLP | 34.8 24.5 | 5.8 3.9 | 10.7 8.8 |
| French trial (31 ) | Dank M | 2008 | 333 | IFL FP4w | 31.8 25.8 | 5.0 4.2 | 9.0 8.7 |
| FFCD-Unicancer-GERCOR (32 ) | Guimbaud R | 2014 | 416 | FOLFIRI-ECX ECX-FOLFIRI | 39.2 37.8 | 5.3 5.8 | 9.5 9.7 |
| TOGA (40) | Bang YL | 2010 | 594 | X(FU)P X(FU)P-T | 35 47 | 5.5 6.7 | 11.1 13.8 |
| TRIO-013/LOGiC (41) | Hech R | 2013 | 545 | XOx XOx-L | 40 53 | 5.4 6.0 | 10.5 12.2 |
| AVAGAST (46) | Otshu A | 2011 | 774 | X(FU)P X(FU)P-Bev | 37.4 46 | 5.3 6.7 | 10.1 12.1 |
| AVATAR (47) | Shen J | 2015 | 202 | XP XP-Bev | 33.7 40.7 | 6.0 6.3 | 11.4 10.5 |
| EXPAND (43) | Lordick F | 2013 | 904 | XP XP-Cet | 30 30 | 4.4 5.6 | 9.4 10.7 |
| REAL-3 (44) | Waddell T | 2013 | 553 | EOX EOX-Pan | 42 46 | 7.4 6.0 | 11.3 8.8 |